Treatment with statin before PCI intervention reduces MACE in patients with ACS
ACC 2018 Results of the SECURE-PCI trial showed a 28% decrease of MACE in patients treated with avorstatin compared to placebo before PCI intervention after ACS.
This 3-minute education provides a summary of just presented scientific data, recorded during the ACC 2018. The objective is to provide a brief commentary and potential implications of these findings.
Otavio Berwanger, MD, is a cardiologist and clinical epidemiologist in the Brazilian Clinical Research Institute in São Paulo, Brasil.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.